SPRY today
$3.94+$0.13 (+3.54%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $3.90
Key levels
Resistance$5.20
Resistance$4.44
Support$3.90
Support$3.52
Latest news & SEC filings
AnalystCantor Fitzgerald keeps Overweight rating on ARS Pharmaceuticals
AnalystRaymond James lowers ARS Pharmaceuticals rating to Outperform
EarningsARS Pharmaceuticals Posts Q3 2026 Results
EarningsARS Pharmaceuticals Analysts Lower Forecasts After Weak Q3 Results
All SPRY news →About ARS Pharmaceuticals
ARS Pharmaceuticals is a biopharmaceutical company behind neffy, a needle-free nasal spray that delivers epinephrine to treat severe allergic reactions, including anaphylaxis. Regulators across North America, Europe, and Asia have cleared the product, which reaches customers through partners in markets outside the United States. The company also runs clinical programs testing intranasal epinephrine for chronic urticaria. Its customers are allergy specialists, pediatricians, and primary care physicians and their patients.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
ARS Pharmaceuticals, Inc. (SPRY)
What Is the Price Target for SPRY?
SEPT Low Target
$17.00
SEPT Mid Target
$20.00
SEPT High Target
$24.00
Analyst Consensus
$20.00
Is SPRY a Buy or Sell Right Now?
Thesis
- •Revenue growing -5.5% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SPRY.
Start Free Trial →Is SPRY Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$15.07
17
Moat Score
NONE
3/9
Piotroski Score
-1.2
Altman Z-Score
What Is Smart Money Doing with SPRY?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Karas Eric | officer | Buy | 25,000 | $38K | Jun 12, 2026 |
| Karas Eric | officer | Sale | 25,000 | $250K | Jun 12, 2026 |
| Fitzpatrick Alexander A | officer | Sale | 3,355 | $34K | Jun 12, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SPRY Growth Story
Revenue YoY
-5.5%
3yr Revenue CAGR
300.1%
EPS Growth YoY
-2275%
FCF Growth YoY
-1418.5%
Revenue Trend
ACCELERATING
Dark Pool Trades for SPRY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SPRY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:21:30 | $3.95 | 1,300 | $$5K | BUY |
| 18:12:03 | $3.92 | 1,700 | $$7K | MIDPOINT |
| 18:12:03 | $3.92 | 1,500 | $$6K | MIDPOINT |
| 18:12:03 | $3.92 | 1,500 | $$6K | MIDPOINT |
| 18:12:03 | $3.92 | 1,400 | $$5K | MIDPOINT |
5 dark pool trades shown · $$29K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About SPRY
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for SPRY. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $SPRY -- Neutral Bounced back with 68% buying after prior session selling. Uptrend holds while above $9.57. $10 psychological level is the next resistance to watch. The Play: Watch for...
Join 3,500+ traders discussing SPRY in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ARS Pharmaceuticals, Inc. (SPRY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SPRY — frequently asked questions
What is SPRY stock price today?
ARS Pharmaceuticals, Inc. (SPRY) is at $3.94, up 3.54% (+$0.13) at the Nov 13, 2026 close.
Why is SPRY stock moving today?
Latest SPRY news — Nov 6, 2026: Cantor Fitzgerald keeps Overweight rating on ARS Pharmaceuticals · Nov 6, 2026: Raymond James lowers ARS Pharmaceuticals rating to Outperform
Why did SPRY stock move on Nov 6, 2026?
ARS Pharmaceuticals (SPRY) shares closed at $2.79, up 4.89% on heavy volume of 5.66 million shares, despite a mixed news flow. The company reported weak Q3 2026 results, prompting analysts to lower their forecasts, while Raymond James downgraded the stock to Outperform.
What is the SPRY price target?
The average analyst price target for SPRY is $20.00, ranging from $17 to $24, based on 3 analysts. Latest: Raymond James downgrade on Nov 6, 2026.
What do analysts rate SPRY?
Analyst ratings for SPRY: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did SPRY beat earnings?
SPRY last reported on Nov 5, 2026: EPS -$0.36 vs -$0.30 expected — a miss of 18.0%.
Does SPRY pay a dividend?
SPRY does not currently pay a dividend.
How much debt does SPRY have?
ARS Pharmaceuticals, Inc. reported $97M of debt and $8M of cash (Jun 30, 2026).
What are SPRY support and resistance levels?
Support: $3.90, $3.52, $2.44. Resistance: $4.44, $5.20, $6.12.
What are insiders doing with SPRY?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on SPRY?
Nov 6, 2026: Cantor Fitzgerald keeps Overweight rating on ARS Pharmaceuticals · Nov 6, 2026: Raymond James lowers ARS Pharmaceuticals rating to Outperform · Nov 6, 2026: ARS Pharmaceuticals Posts Q3 2026 Results